In vivo antitumor activity of choline kinase inhibitors: A novel target for anticancer drug discovery

Cancer Research

Volumn 59, Issue 13, 1999, Pages 3112-3118

  Hernández Alcoceba, Rubén ^a   Fernández, Félix ^a   Lacal, Juan Carlos ^a,b  

^a CSIC   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE KINASE; CHOLINE KINASE INHIBITOR; ENZYME INHIBITOR; FK 19; FK 21; JCR 1043B; JCR 59C; JCR 791B; JCR 795B; JCR 947A; JCR 947B; JCR 987B; MN 168B; MN 276B; MN 280B; MN 284B; MN 288B; MN 304B; MN 305B; MN 308B; MN 332B; MN 336B; MN 352B; MN 356B; MN 58B; MN 82B; MN 90B; MN 94B; MN 96B; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CHOLINE KINASE; COLONIC NEOPLASMS; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0038089964     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. Oncogenes and signal transduction. Cell, 64: 281-302, 1991.
2. Lewin, B. Oncogenic conversion by regulatory changes in transcription factors. Cell, 64: 303-312, 1991.
3. Cross, M., and Dexter, T. M. Growth factors in development, transformation and tumorigenesis. Cell, 64: 271-280, 1991.
4. Hockenbery, D., Nunez, G., Milliam, C., Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.), 348: 334-336, 1990.
5. Powis, G. Pharmacological intervention with signal transduction. In: P. Workman (ed.), New Approaches in Cancer Pharmacology: Drug Design and Development, pp. 39-54. Berlin: Springer-Verlag, 1994.
6. Gibbs, J. B., and Oliff, A. Pharmaceutical research in molecular oncology. Cell, 79: 193-198, 1994.
7. Friend, S. H., and Oliff, A. Emerging uses for genomic information in drug discovery. N. Engl. J. Med., 338: 125-126, 1998.
8. Fraumeni, J. F., Jr, Devesa, S. S., Hoover, R. N., and Kinlen, L. J. Epidemiology of cancer. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 4, pp. 150-181. Philadelphia: J. B. Lippincott Co., 1993.
9. De Vita, V. T., Jr. Principles of chemotherapy. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles and Practice of Oncology, Ed. 4, pp. 276-292. Philadelphia: J. B. Lippincott Co., 1993.
10. Unger, C. Current concepts of treatment in medical oncology: new anticancer drugs. J. Cancer Res. Clin. Oncol., 122: 189-198, 1996.
11. Lacal, J. C., and Carnero, A. Regulation of Ras proteins and their involvement in signal transduction pathways (Review). Oncol. Rep., 1: 677-693, 1994.
12. Lacal, J. C. Regulation of proliferation and apoptosis by Ras and Rho GTPases through specific phospholipid-dependent signaling. FEBS Lett., 410: 73-77, 1997.
13. Pelech, S. L., and Vance, D. E. Signal transduction via phosphatidylcholine cycles. Trends Biochem. Sci., 14: 28-30, 1989.
14. Plevin, R., Cook, S. J., Palmer, S., and Wakelam, M. J. O. Multiple sources of sn-1,2-diacylglycerol in platelet-derived growth factor-stimulated Swiss 3T3 fibroblast. Biochem. J., 279: 559-565, 1991.
15. Nishizuka, Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science (Washington DC), 258: 607-614, 1992.
16. Carnero, A., and Lacal, J. C. Phospholipase-induced maturation of Xenopus laevis oocytes: mitogenic activity of generated metabolites. J. Cell. Biochem., 52: 440-448, 1993.
17. Carnero, A., Cuadrado, A., del Peso, L., and Lacal, J. C. Activation of type D phospholipase by serum and ras-induced transformation in NIH3T3 cells. Oncogene, 9: 1387-1395, 1994.
18. Carnero, A., Dolfi, F., and Lacal, J. C. Ras-p21 activates phospholipase D and A2, but no phospholipase C or PKC, in Xenopus laevis oocytes. J. Cell. Biochem., 54: 478-486, 1994.
19. Billah, M. M., and Anthes, J. C. The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem. J., 269: 281-291, 1990.
20. Agwu, D. E., McPhail, L. C., Chabot, M. C., Daniel, L. W., Wykle, R. L., and McCall, C. E. Choline-linked phosphoglycerides. A source of phosphatidic acid and diglycerides in stimulated neulrophils. J. Biol. Chem., 264: 1405-1413, 1989.
21. Lacal, J. C. Diacylglycerol production in Xenopus laevis oocytes after microinjection of p21ras proteins is a consequence of activation of phosphatidylcholine metabolism. Mol. Cell. Biol., 10: 333-340, 1990.
22. Cook, S. J., Briscoe, C. P., and Wakelam, M. J. O. The regulation of phospholipase D activity and its role in sn-1,2-diacylglycerol formation in bombesin and and phorbol 12-myristate 13-acetate-stimulated Swiss 3T3 cells. Biochem. J., 280: 431-438, 1991.
23. Moolenaar, W. H., Kruijer, W., Tilly, B. C., Werlaan, I., Bierman, A. J., and de Laat, S. W. Growth factor-like action of phosphatidic acid. Nature (Lond.), 323: 171-173, 1986.
24. van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., and Moolenaar, W. H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins. Cell, 59: 45-54, 1989.
25. Fukami, K., and Takenawa, T. Phosphatidic acid that accumulates in platelet-derived growth factor-stimulated Balb/c 3T3 cells is a potential mitogenic signal. J. Biol. Chem., 267: 10988-10993, 1992.
26. Cuadrado, A., Carnero, A., Dolfi, F., Jiménez, B., and Lacal, J. C. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene, 8: 2959-2968, 1993.
27. Jiménez, B., del Peso, L., Montaner, S., Esteve, P., and Lacal, J. C. Generation of phosphorylcholine as an essential event in the activation of Raf-1 and MAP-kinases in growth factors-induced mitogenic stimulation. J. Cell. Biochem., 57: 141-149, 1995.
28. Hernandez-Alcoceba, R., Saniger, L., Campos, J. Nun̄ez, M. C., Khaless, F., Gallo, M. A., Espinosa, A., and Lacal, J. C. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene, 15: 2289-2301, 1997.
29. 31P NMR spectroscopy. J. Biol. Chem., 262: 14875-14878, 1987.
30. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Cancer Res., 48: 5112-5118, 1988.
31. Ruiz-Cabello, J., and Cohen, J. S. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed., 5: 226-233, 1992.
32. 31P MRS of experimental tumours. NMR Biomed., 6: 345-365, 1993.
33. Smith, T. A. D., Bush, C., Jameson, C., Titley, J. C., Leach, M. O., Wilman, D. E. V., and McCready, V. R. Phospholipid metabolites., prognosis and proliferation in human breast carcinoma. NMR Biomed., 6: 318-323, 1993.
34. Bhakoo, K. K., Williams, S. R., Florian, C. L., Land, H., and Noble, M. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res., 56: 4630-4635, 1996.
35. Lacal, J. C., Moscat, J., and Aaronson, S. A. Novel source of 1,2-diacylglicerol elevated in cells transformed by Ha-ras oncogene. Nature (Lond.), 330: 269-271, 1987.
36. Macara, I. G. Elevated phosphocholine concentration in ras-transformed NIH3T3 cells arises from increased choline kinase activity, not from phosphatidylcholine breakdown. Mol. Cell. Biol., 9: 325-328, 1989.
37. Teegarden, D., Taparowsky, E. J., and Kent, C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J. Biol. Chem., 265: 6042-6047, 1990.
38. Ratnam, S., and Kent, C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch. Biochem. Biophys., 323: 313-322, 1995.
39. Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., and Perucho, M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.
40. Weinberg, R. A. Oncogenes and the molecular origins of cancer. Cold Spring Harbor Monograph Series, 18. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
41. Gillies, R. J., Didier, N., and Denton, M. Determination of cell number in monolayer cultures. Anal. Biochem., 159: 109-113, 1986.
42. Schnall, S. and Macdonald, J. S. Gastrointestinal cancers. In: J. S. Macdonald, D. G. Haller, and R. J. Mayer (eds.), Manual of Oncologic Therapeutics, Ed. 3, pp. 170-184. Philadelphia: J. B. Lippincott Co., 1995.
43. Staley, C. A., Parikh, N. U., and Gllick, G. E. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ., 8: 269-274, 1997.
44. Cannon, J. G. Structure-activity aspects of hemicholinium-3 (HC-3) and its analogs and congeners. Med. Res. Rev., 14: 505-531, 1994.
45. Helene, C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur. J. Cancer, 27: 1466-1477, 1991.
46. Gibbs, J. B., Oliff, A., and Kohl, N. E.,. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
47. Chang, C. J., Ashendel, C. L., Geahlen, R. L., McLaughlin, J. L., and Waters, D. J. Oncogene signal transduction inhibitors from medicinal plants. In Vivo, 10: 185-190, 1996.
48. Spector, D. H., Varmus, H. E., and Bishop, J. M. Nucleotide sequences related to the transforming gene of avian sarcoma virus are present in the DNA of uninfected vertebrates. Proc. Natl. Acad. Sci. USA, 75: 4102-4106, 1978.
49. Hunter, T. Cooperation between oncogenes. Cell, 64: 249-270, 1991.
50. Powis, G., Hill, S. R., Frew, T. J., and Sherrill, K. W. Inhibitors of phospholipid intracellular signaling as antiproliferative agents. Med. Res. Rev., 15: 121-138, 1995.
51. Workman, P. In: P. Workman (ed.), New Approaches in Cancer Pharmacology: Drug Design and Development, Vol. II. Berlin: Springer-Verlag, 1994.
52. Rao, R. N. Targets for cancer therapy in the cell cycle pathway. Curr. Opin. Oncol., 8: 516-524, 1996.
53. Carboni, J. M., Yan, N., Cox, A. D., Bustelo, X., Graham, S. M., Lynch, M. J., Weinmann, R., Seizinger, B. R., Der, C. J., Barbacid, M. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras/TC21, transformation. Oncogene, 10: 1905-1913, 1995.
54. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., deSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., and Hamilton, K. Inhibition of famesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
55. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
56. Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., and Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (Washington DC), 265: 1093-1095, 1994.
57. Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., and Lydon, N. B. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA, 92: 2558-2562, 1995.
58. Levitzki, A., and Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science (Washington DC), 207: 1782-1788, 1995.
59. Klhos, W. D., Fry, D. W., and Kraker, A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol., 9: 562-568, 1997.
60. del Peso, L., Hernández, R., Esteve, P., and Lacal, J. C. Activation of phospholipase D by Ras proteins is independent of Protein Kinase C. J. Cell. Biochem., 60: 1-10, 1996.
61. del Peso, L., Lucas, L., Esteve, P., and Lacal, J. C. Activation of phospholipase D by growth factors and oncogenes in murine fibroblasts follow alternative but cross-talking pathways. Biochem. J., 322: 519-528, 1997.
62. Exton, J. H. Signaling through phosphatidylcholine breakdown. J. Biol. Chem., 263: 1-4, 1990.
63. Eibl, H., Hilgard, E., and Unger, C. (eds.). Alkylphosphocholines: new drugs in cancer therapy. Prog. Exp. Tumor Res., Vol. 34, 1992.
64. Baburina, I., and Jackowski, S. Apoptosis triggered by 1-O-octadecyl-2-O-methyl-ras-glycero-3-phosphocholine is prevented by increased expression of CTP:phosphocholine cytidylyltransferase. J. Biol. Chem., 273: 2169-2173, 1998.
65. 2+ signaling by antitumor ether lipid analogues. Cancer Res., 50: 4458-4463, 1990.
66. Überall, F., Oberhuber, H., Maly, K., Zaknun, J., Demuth, L., and Grunicke, H. H. Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res., 51: 807-812, 1991.
67. Pawelczyk, T., and Lowenstein, J. M. Inhibition of phospholipase C delta by hexadecylphosphorylcholine and lysophospholipids with antitumor activity. Biochem. Pharmacol., 45: 493-497, 1993.
68. Berkovic, D., Berkovic, K., Fleer, E. A., Eibl, H., and Unger, C. Inhibition of calcium-dependent protein kinase C by hexadecylphospho-choline and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines. Eur. J. Cancer, 30: 509-515, 1994.
69. Wieder, T., Zhang, Z., Geilen, C. C., Orfanos, C. E., Giuliano, A. E., and Cabot, M. C. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. Cancer Lett., 100: 71-79, 1996.